25 results
8-K
EX-99.1
ANVS
Annovis Bio Inc
13 May 24
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
4:05pm
months ended March 31, 2024 was $6.7 million, which included a $6.7 million non-cash gain from change in fair value of liability-classified warrants
8-K
EX-10.2
ANVS
Annovis Bio Inc
21 Mar 24
Entry into a Material Definitive Agreement
5:23pm
for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which
424B5
ANVS
Annovis Bio Inc
18 Mar 24
Prospectus supplement for primary offering
10:00pm
December 31 2022 which is incorporated by reference in this prospectus supplement, there were material amounts inappropriately classified as research … and development expense which should have been classified as prepaid assets and other assets. We are taking steps to remediate the material weakness
424B5
m753ql7
18 Mar 24
Prospectus supplement for primary offering
8:51pm
8-K
EX-10.2
x5l3krts9xy3mlcy250b
15 Mar 24
Entry into a Material Definitive Agreement
5:22pm
424B5
wzu1l a06kpu2
1 Nov 23
Prospectus supplement for primary offering
12:24pm
424B5
26ls7v01vly3klndr4
30 Oct 23
Prospectus supplement for primary offering
5:27pm
10-K
bpifhy89
25 Mar 20
Annual report
4:45pm
424B4
duum6p
30 Jan 20
Prospectus supplement with pricing info
6:07am
S-1/A
6lsoo tyyq3zb18
8 Aug 19
IPO registration (amended)
5:23pm